Fasedienol
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
8
Phase 3
6
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT01217788)
Timeline
Indications
Mechanism of action
- Gamma-amino-N-butyrate transaminaseMODULATOR
ABAT modulator
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@]12C=CC[C@H]1[C@@H]1CCC3=C[C@@H](O)CC[C@]3(C)[C@H]1CC2- Mol. weight
- 272.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095042 ↗
Also known as
- ph94b
- ph94b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06615557 | Phase 3 | Sep 16, 2024 | VistaGen Therapeutics, Inc. |
| NCT06358651 | Phase 3 | Mar 28, 2024 | VistaGen Therapeutics, Inc. |
| NCT05030350 | Phase 3 | Oct 1, 2021 | VistaGen Therapeutics, Inc. |
| NCT05011396 | Phase 3 | Aug 30, 2021 | The Medical Research Network, LLC, VistaGen Therapeutics, Inc. |
| NCT04754802 | Phase 3 | May 24, 2021 | The Medical Research Network, LLC, VistaGen Therapeutics, Inc. |
| NCT04404192 | Phase 2 | Nov 30, 2020 | VistaGen Therapeutics, Inc. |
| NCT02622958 | Phase 3 | Mar 1, 2014 | Pherin Pharmaceuticals, Inc., The Medical Research Network, LLC |
| NCT01217788 | Phase 2 | Feb 1, 2008 | Pherin Pharmaceuticals, Inc., The Medical Research Network, LLC |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VistaGen Therapeutics, Inc. | For profit | 6 | 6 | 2 | 2020 |
| The Medical Research Network, LLC | Academic/Hospital | 4 | 0 | 2 | 2008 |
| Pherin Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2008 |
3 organizations
Page 1 / 1